Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EAGLE: Neoadjuvant Erbitux in Oral/Oropharyngeal Cancer
NCT01434394Phase 3Completed
- Sponsor
- Shanghai Jiao Tong University School of Medicine
- Start
- Aug 2011
- Primary completion
- Oct 2014
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of KL-140 in oral squamous cell carcinoma (OSCC), oropharyngeal squamous cell carcinoma (OPSCC), sponsored by Shanghai Jiao Tong University School of Medicine. Started Aug 2011; status: completed.
02
Drugs
KL-140
03
Conditions
oral squamous cell carcinoma (OSCC)oropharyngeal squamous cell carcinoma (OPSCC)
Beyond the preview
Go deeper on NCT01434394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01434394.